Repligen’s (RGEN) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $190.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. Guggenheim assumed coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a neutral rating on the stock. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a hold rating to a buy rating and decreased their price objective for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Stephens restated an overweight rating and set a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. reduced their target price on Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $189.57.

Repligen Trading Down 2.4 %

Shares of RGEN stock opened at $161.67 on Wednesday. The stock has a market cap of $9.06 billion, a P/E ratio of 646.71, a price-to-earnings-growth ratio of 5.98 and a beta of 0.95. Repligen has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a 50 day simple moving average of $134.92 and a 200 day simple moving average of $166.00.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same period in the previous year, the firm earned $0.53 EPS. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. On average, research analysts predict that Repligen will post 1.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Repligen during the 4th quarter valued at approximately $48,208,000. Bank of New York Mellon Corp increased its position in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after buying an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its stake in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its holdings in Repligen by 448.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock valued at $20,293,000 after buying an additional 92,268 shares during the period. Finally, Brown Capital Management LLC boosted its position in Repligen by 5.8% during the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after acquiring an additional 83,416 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.